Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR E746_T751>I
EGFR E746_T751>I - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had prior chemotherapy but no treatment with TKIs. 19 patients had unspecified uncommon EGFR mutations, including single mutations other than ex19del and L858R and double mutations. Of those 19 patients, 7 were treated with erlotinib and 12 were treated with gefitinib. Objective response and disease control rate between erlotinib and gefitinib were not significantly different. The study failed to satisfy the primary endpoint of demonstrating statistical noninferiority in PFS of gefitinib.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6186
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2334
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Does Not Support
- Drug
- Gefitinib
- Evidence Level
- C
- Clinical Significance
- Reduced Sensitivity
- Pubmed
- 27022112
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Gefitinib | N/A | false |